İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - azithromycinum mónóhýdrat - filmuhúðuð tafla - 500 mg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - azithromycinum díhýdrat - mixtúruduft, dreifa - 40 mg/ml

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios normon s.a. - azithromycinum díhýdrat - filmuhúðuð tafla - 500 mg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - tiotropii bromidum inn - innöndunarduft, hart hylki - 10 míkróg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - fluconazolum inn - hart hylki - 200 mg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - fluconazolum inn - hart hylki - 50 mg

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil stutt og long-term - litlaræxli - Æxlishemjandi lyf - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - kyrningahvítblæði, mergbólga, bráð - Æxlishemjandi lyf - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atópísk - aðrar húðsjúkdómar - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

galderma nordic ab - doxycyclinum inn - hart hylki með breyttan losunarhraða - 40 mg